Jpmorgan Chase & CO Omeros Corp Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Omeros Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 24,233 shares of OMER stock, worth $102,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,233
Previous 26,628 8.99%
Holding current value
$102,990
Previous $91,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$3.04 - $4.23 $7,280 - $10,130
-2,395 Reduced 8.99%
24,233 $98,000
Q1 2024

May 10, 2024
SELL
$2.88 - $4.89 $42,298 - $71,819
-14,687 Reduced 35.55%
26,628 $91,000
Q4 2023

Feb 12, 2024
SELL
$1.08 - $3.63 $12,704 - $42,699
-11,763 Reduced 22.16%
41,315 $135,000
Q3 2023

Nov 14, 2023
BUY
$2.81 - $5.69 $10,973 - $22,219
3,905 Added 7.94%
53,078 $154,000
Q2 2023

Aug 11, 2023
BUY
$4.45 - $7.57 $210,315 - $357,773
47,262 Added 2473.16%
49,173 $267,000
Q1 2023

May 11, 2023
BUY
$2.48 - $5.22 $416 - $876
168 Added 9.64%
1,911 $8,000
Q4 2022

Feb 13, 2023
SELL
$1.75 - $3.96 $2,066 - $4,676
-1,181 Reduced 40.39%
1,743 $4,000
Q3 2022

Nov 14, 2022
BUY
$3.09 - $7.46 $1,001 - $2,417
324 Added 12.46%
2,924 $9,000
Q2 2022

Aug 11, 2022
SELL
$1.92 - $6.28 $63,590 - $207,993
-33,120 Reduced 92.72%
2,600 $7,000
Q1 2022

May 11, 2022
BUY
$5.07 - $7.2 $32,868 - $46,677
6,483 Added 22.17%
35,720 $215,000
Q4 2021

Feb 10, 2022
BUY
$5.67 - $8.54 $12,547 - $18,899
2,213 Added 8.19%
29,237 $188,000
Q3 2021

Nov 12, 2021
BUY
$13.4 - $16.3 $362,121 - $440,491
27,024 New
27,024 $373,000

Others Institutions Holding OMER

# of Institutions
113
Shares Held
25.5M
Call Options Held
317K
Put Options Held
556K
View Full List

About OMEROS CORP

OMER Quotes by TradingView
  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $267M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email